Zolgensma
-
The US Food and Drug Administration approved a treatment last week for a genetic disease called spinal muscular atrophy that causes infants’ muscles to waste away, potentially killing them before age of two. The price tag: $2.125 million for a one-time treatment. The list price immediately reignited controversy around the rising costs of drugs and how to…